Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae

Christina Kratzer1, Wolfgang Graninger, Karin Macfelda

  • 1Department of Internal Medicine I, Division of Infectious Diseases and Tropical Diseases, Medical University of Vienna, Vienna, Austria.

Abstract

Insights

Moxifloxacin effectively kills intracellular non-typeable Haemophilus influenzae (NTHi), a common respiratory pathogen. This antibiotic shows rapid efficacy, making it a potential treatment for recurrent NTHi infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Non-typeable Haemophilus influenzae (NTHi) is a significant cause of respiratory infections.
  • NTHi can invade epithelial cells, evading immune responses and antibiotics.
  • Understanding intracellular NTHi activity is crucial for effective treatment.

Purpose of the Study:

  • To evaluate the efficacy of five common antibiotics against intracellular NTHi.
  • To compare the killing activity of ampicillin, azithromycin, telithromycin, ciprofloxacin, and moxifloxacin.
  • To determine the impact of antibiotic concentration and exposure time on intracellular NTHi viability.

Main Methods:

  • Human bronchial epithelial cells infected with NTHi 77.
  • Treatment with antibiotics (ampicillin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin) at 1 mg/l or 10 mg/l for 4 or 8 hours.
  • Quantification of viable intracellular bacteria after cell lysis.

Main Results:

  • Moxifloxacin demonstrated rapid and significant reduction of intracellular NTHi.
  • At 1 mg/l, moxifloxacin achieved 94-98% killing within 4-8 hours.
  • At 10 mg/l, moxifloxacin, ciprofloxacin, and telithromycin showed high efficacy (74.7-99.7%) after 4 hours.

Conclusions:

  • Moxifloxacin exhibits potent in vitro activity against intracellular NTHi.
  • Its combined extracellular and intracellular efficacy suggests potential for treating recurrent respiratory infections.
  • Further investigation into moxifloxacin's role in NTHi treatment is warranted.